Breath Analysis to Diagnose Lung Cancer
CATOCOV
Analysis of Volatile Organic Compounds in Exhaled Air as a Diagnostic Tool for Thoracic Cancers
3 other identifiers
interventional
1,500
1 country
7
Brief Summary
Determination of volatile organic compounds to discriminate patients with lung cancer from healthy smokers and non-smokers healthy subjects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable lung-cancer
Started Apr 2019
Longer than P75 for not_applicable lung-cancer
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 7, 2017
CompletedFirst Posted
Study publicly available on registry
August 15, 2017
CompletedStudy Start
First participant enrolled
April 29, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 29, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 29, 2024
CompletedApril 15, 2025
April 1, 2025
5 years
August 7, 2017
April 10, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Discriminating power of VOCs
Discriminating power of VOCs using discriminant analyzes using innovative data mining methods based on multi-objective combinatorial optimization.
34 months
Study Arms (2)
patients
EXPERIMENTALPatients with bronchopulmonary cancer who have not yet received therapeutic treatment.
controls
ACTIVE COMPARATORThe controls consisted of 2 groups: smokers and non-smokers.
Interventions
The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler. The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)
Eligibility Criteria
You may qualify if:
- patients with histologically proven lung cancer
- Controls:
- healthy smoker or non-smoker subjects
- without respiratory diseases excepted chronic obstructive pulmonary disease.
You may not qualify if:
- oral or facial malformation
- incomprehension of maneuvers for the collection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital, Lillelead
- Institut National de Recherche en Informatique et en Automatiquecollaborator
- Institut Pasteur de Lillecollaborator
- Institut MinesTelecom (IMT)collaborator
Study Sites (7)
Institut Pasteur - Centre de Prévention et d'Education à la Santé (CPES)
Lille, 59000, France
Hôpital Calmette, CHU
Lille, France
Hopital Victor Provo
Roubaix, France
Centre Hospitalier de Saint Quentin
Saint-Quentin, France
Chu Amiens Salouël
Salouël, France
Ch Seclin - Seclin
Seclin, France
Clinique Teissier
Valenciennes, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sébastien Hulo, MD
University Hospital, Lille
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 7, 2017
First Posted
August 15, 2017
Study Start
April 29, 2019
Primary Completion
April 29, 2024
Study Completion
April 29, 2024
Last Updated
April 15, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share